With a mega investment of 6.5 billion dollars, Eli Lilly and Company has plans to develop a next-generation synthetic medicine active pharmaceutical product facility in Texas, USA. The facility will focus on manufacturing the company's pipeline of small molecule medicines across therapeutic areas.
Read on